

# Charlie Strange

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6276256/publications.pdf>

Version: 2024-02-01

199  
papers

13,750  
citations

34016

52  
h-index

22102

113  
g-index

213  
all docs

213  
docs citations

213  
times ranked

11007  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclophosphamide versus Placebo in Scleroderma Lung Disease. <i>New England Journal of Medicine</i> , 2006, 354, 2655-2666.	13.9	1,421
2	Management of Spontaneous Pneumothorax. <i>Chest</i> , 2001, 119, 590-602.	0.4	1,119
3	Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. <i>New England Journal of Medicine</i> , 2011, 364, 1595-1606.	13.9	922
4	An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1004-1014.	2.5	832
5	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	5.2	754
6	A Randomized Study of Endobronchial Valves for Advanced Emphysema. <i>New England Journal of Medicine</i> , 2010, 363, 1233-1244.	13.9	704
7	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1026-1034.	2.5	411
8	Neurocognitive Impairment in Obstructive Sleep Apnea. <i>Chest</i> , 2012, 141, 1601-1610.	0.4	324
9	A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1151-1164.	2.5	253
10	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 748-761.	2.5	236
11	Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2178.	3.8	208
12	Delay in Diagnosis of $\alpha$ 1-Antitrypsin Deficiency. <i>Chest</i> , 2005, 128, 1989-1994.	0.4	196
13	Treatment of Spontaneous Pneumothorax. <i>Chest</i> , 1997, 112, 789-804.	0.4	166
14	Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. <i>Lancet Respiratory Medicine</i> , 2013, 1, 445-452.	5.2	159
15	Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1337-1348.	2.5	159
16	The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 668-682.	0.5	148
17	Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. <i>Journal of Rheumatology</i> , 1993, 20, 838-44.	1.0	143
18	Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 91-98.	2.5	138

#	ARTICLE	IF	CITATIONS
19	Pneumothorax in Cystic Fibrosis. <i>Chest</i> , 2005, 128, 720-728.	0.4	136
20	Empyema Thoracis. <i>Chest</i> , 1995, 107, 1532-1537.	0.4	129
21	Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1997, 40, 743-751.	6.7	123
22	Pulmonary Manifestations of Systemic Lupus Erythematosus. <i>Clinics in Chest Medicine</i> , 2010, 31, 479-488.	0.8	122
23	Talc Slurry Pleurodesis. <i>Chest</i> , 1995, 107, 1707-1712.	0.4	117
24	Interstitial lung disease in the patient who has connective tissue disease. <i>Clinics in Chest Medicine</i> , 2004, 25, 549-559.	0.8	117
25	Long-Term Effects of Inhaled Corticosteroids on FEV <sub>1</sub> in Patients with Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2003, 138, 969.	2.0	115
26	Limitations to the 6-Minute Walk Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma. <i>Journal of Rheumatology</i> , 2009, 36, 330-336.	1.0	114
27	Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. <i>Thorax</i> , 2007, 62, 806-813.	2.7	108
28	Smoking duration, respiratory symptoms, and COPD in adults aged &gt;=45 years with a smoking history. <i>International Journal of COPD</i> , 2015, 10, 1409.	0.9	107
29	The Clinician's Perspective on Pneumothorax Management. <i>Chest</i> , 1997, 112, 822-828.	0.4	104
30	Biologic Lung Volume Reduction in Advanced Upper Lobe Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 791-798.	2.5	103
31	Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension. <i>Chest</i> , 2008, 134, 775-782.	0.4	99
32	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007, 56, 1676-1684.	6.7	93
33	Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. <i>BMC Pulmonary Medicine</i> , 2007, 7, 10.	0.8	92
34	Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. <i>Annals of Behavioral Medicine</i> , 2007, 33, 22-28.	1.7	92
35	Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 390-396.	2.4	83
36	Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. <i>Annals of the American Thoracic Society</i> , 2016, 13, 803-810.	1.5	83

#	ARTICLE	IF	CITATIONS
37	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , 2020, 29, 200287.	3.0	82
38	Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit*. <i>Critical Care Medicine</i> , 2006, 34, 2974-2978.	0.4	81
39	Alpha-1 Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Clinical Practice Guideline. <i>Canadian Respiratory Journal</i> , 2012, 19, 109-116.	0.8	80
40	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 644-652.	2.5	77
41	<i>IL10</i> Polymorphisms Are Associated with Airflow Obstruction in Severe $\alpha$ 1-Antitrypsin Deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 38, 114-120.	1.4	72
42	Therapeutic Effects of Adipose Stem Cells from Diabetic Mice for the Treatment of Type 2 Diabetes. <i>Molecular Therapy</i> , 2018, 26, 1921-1930.	3.7	72
43	Circulating polymers in $\alpha$ 1-antitrypsin deficiency. <i>European Respiratory Journal</i> , 2014, 43, 1501-1504.	3.1	69
44	Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. <i>International Journal of COPD</i> , 2018, Volume 13, 2587-2601.	0.9	69
45	Intraleural Streptokinase in Experimental Empyema. <i>The American Review of Respiratory Disease</i> , 1993, 147, 962-966.	2.9	68
46	Mortality in Individuals With Severe Deficiency of $\alpha$ 1-Antitrypsin*. <i>Chest</i> , 2005, 127, 1196.	0.4	67
47	A Comparison of Rotation and Nonrotation in Tetracycline Pleurodesis. <i>Chest</i> , 1993, 104, 1763-1766.	0.4	66
48	The histology of experimental pleural injury with tetracycline, empyema, and carrageenan. <i>Experimental and Molecular Pathology</i> , 1989, 51, 205-219.	0.9	65
49	$\alpha$ 1-Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction. <i>Diabetes</i> , 2017, 66, 970-980.	0.3	62
50	Chest Ultrasound for "Dummies". <i>Chest</i> , 2003, 123, 332-333.	0.4	58
51	Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 687-695.	0.7	57
52	Pulmonary hypertension in interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 452-455.	1.2	55
53	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019, 71, 2059-2067.	2.9	55
54	Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 508-515.	2.5	53

#	ARTICLE	IF	CITATIONS
55	Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients. <i>Chest</i> , 2012, 142, e1S-e111S.	0.4	52
56	The Clinician's Perspective on Parapneumonic Effusions and Empyema. <i>Chest</i> , 1993, 103, 259-261.	0.4	51
57	The Prevalence of Alpha-1 Antitrypsin Deficiency Among Patients Found to Have Airflow Obstruction. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 352-358.	0.7	51
58	Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy. <i>Stem Cells Translational Medicine</i> , 2018, 7, 11-19.	1.6	51
59	Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New $\alpha$ 1-Proteinase Inhibitor, Zemaira. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2006, 3, 17-23.	0.7	50
60	Results of a Survey of Patients with Alpha-1 Antitrypsin Deficiency. <i>Respiration</i> , 2006, 73, 185-190.	1.2	50
61	$\alpha$ 1-Antitrypsin Augmentation Therapy for $PI^*MZ$ Heterozygotes. <i>Chest</i> , 2008, 134, 831-834.	0.4	50
62	Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma. <i>Journal of Rheumatology</i> , 1992, 19, 1716-23.	1.0	50
63	Asthma and allergy in alpha-1 antitrypsin deficiency. <i>Respiratory Medicine</i> , 2006, 100, 1384-1391.	1.3	49
64	Respiratory and lower limb muscle function in interstitial lung disease. <i>Chronic Respiratory Disease</i> , 2016, 13, 162-172.	1.0	48
65	Hemodynamic Effects of Epoprostenol in Patients With Systemic Sclerosis and Pulmonary Hypertension. <i>Chest</i> , 2000, 118, 1077-1082.	0.4	46
66	Treatment of Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 2087-2092.	0.4	43
67	Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015, 109, 851-859.	1.3	42
68	Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. <i>Respiratory Research</i> , 2012, 13, 16.	1.4	41
69	Expanded carrier screening panels "does bigger mean better?". <i>Journal of Community Genetics</i> , 2014, 5, 191-198.	0.5	41
70	Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangi leiomyomatosis. <i>European Respiratory Journal</i> , 2019, 53, 1802066.	3.1	41
71	Genetic testing for Alpha1-antitrypsin deficiency. <i>Genetics in Medicine</i> , 2004, 6, 204-210.	1.1	39
72	Baseline Regional Perfusion Impacts Exercise Response to Endobronchial Valve Therapy in Advanced Pulmonary Emphysema. <i>Chest</i> , 2013, 144, 1578-1586.	0.4	39

#	ARTICLE	IF	CITATIONS
73	Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. American Journal of Medicine, 1993, 95, 413-418.	0.6	37
74	Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.. Thorax, 1990, 45, 300-301.	2.7	36
75	Emphysema lung lobe volume reduction: effects on the ipsilateral and contralateral lobes. European Radiology, 2012, 22, 1547-1555.	2.3	36
76	Oropharyngeal swallow physiology and swallowing-related quality of life in underweight patients with concomitant advanced chronic obstructive pulmonary disease. International Journal of COPD, 2018, Volume 13, 2663-2671.	0.9	36
77	Pharmacokinetic comparability of ProlastinÂ®-C to ProlastinÂ® in alpha1-antitrypsin deficiency: a randomized study. BMC Clinical Pharmacology, 2010, 10, 13.	2.5	35
78	Patterns of Emphysema Heterogeneity. Respiration, 2015, 90, 402-411.	1.2	35
79	Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respiratory Research, 2015, 16, 52.	1.4	34
80	Early Inflammatory Response of Minocycline and Tetracycline on the Rabbit Pleura. Chest, 1993, 104, 1585-1588.	0.4	33
81	PLEURAL COMPLICATIONS IN THE INTENSIVE CARE UNIT. Clinics in Chest Medicine, 1999, 20, 317-327.	0.8	32
82	Adverse Events during the Scleroderma Lung Study. American Journal of Medicine, 2011, 124, 459-467.	0.6	30
83	The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. Journal of Behavioral Medicine, 2014, 37, 654-663.	1.1	30
84	Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced Emphysema. Chest, 2019, 155, 928-937.	0.4	29
85	Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. Journal of Asthma, 2016, 53, 720-731.	0.9	28
86	Heritability of Lung Function in Severe Alpha-1 Antitrypsin Deficiency. Human Heredity, 2009, 67, 38-45.	0.4	25
87	Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respiratory Medicine, 2012, 106, 759-768.	1.3	25
88	Prospective impact of illness uncertainty on outcomes in chronic lung disease.. Health Psychology, 2013, 32, 1170-1174.	1.3	25
89	Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population. International Journal of COPD, 2015, 10, 1417.	0.9	25
90	A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangiomyomatosis. Annals of the American Thoracic Society, 2016, 13, 342-349.	1.5	25

#	ARTICLE	IF	CITATIONS
91	Management of Parapneumonic Pleural Effusions and Empyema. <i>Infectious Disease Clinics of North America</i> , 1991, 5, 539-559.	1.9	25
92	Development of Predictive Models for Airflow Obstruction in Alpha-1-Antitrypsin Deficiency. <i>American Journal of Epidemiology</i> , 2009, 170, 1005-1013.	1.6	24
93	Association of cigarette smoking and CRP levels with DNA methylation in $\alpha$ -1 antitrypsin deficiency. <i>Epigenetics</i> , 2012, 7, 720-728.	1.3	24
94	Genetic Testing of Minors for Alpha1-Antitrypsin Deficiency. <i>JAMA Pediatrics</i> , 2006, 160, 531.	3.6	23
95	Inhaled Alpha 1-Antitrypsin: Gauging Patient Interest in a New Treatment. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 411-415.	0.7	23
96	Adipose Stem Cell Therapy Mitigates Chronic Pancreatitis via Differentiation into Acinar-like Cells in Mice. <i>Molecular Therapy</i> , 2017, 25, 2490-2501.	3.7	22
97	Airway Disease in Alpha-1 Antitrypsin Deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 68-73.	0.7	21
98	Characteristics of COPD Patients Using United States Emergency Care or Hospitalization. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2016, 3, 539-548.	0.5	20
99	Pleural macrophages differentially alter mesothelial cell growth and collagen production. <i>Inflammation</i> , 1993, 17, 1-12.	1.7	19
100	Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function. <i>Stem Cell Research and Therapy</i> , 2017, 8, 192.	2.4	19
101	Segmental Approach to Lung Volume Reduction Therapy for Emphysema Patients. <i>Respiration</i> , 2015, 89, 76-81.	1.2	18
102	Detection of alpha-1 antitrypsin deficiency: the past, present and future. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 96.	1.2	18
103	Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy. <i>Respiratory Care</i> , 2018, 63, 690-698.	0.8	17
104	Clathrin-mediated Endocytosis of Alpha-1 Antitrypsin is Essential for its Protective Function in Islet Cell Survival. <i>Theranostics</i> , 2019, 9, 3940-3951.	4.6	17
105	Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2020, 17, 829-838.	1.5	17
106	Double-lumen Endotracheal Tubes. <i>Clinics in Chest Medicine</i> , 1991, 12, 497-506.	0.8	17
107	Differences in Adjustment between Individuals with Alpha-1 Antitrypsin Deficiency (AATD)-Associated COPD and Non-AATD COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 226-234.	0.7	16
108	The Social Environment and Illness Uncertainty in Chronic Obstructive Pulmonary Disease. <i>International Journal of Behavioral Medicine</i> , 2015, 22, 223-232.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Alpha-1 Antitrypsin Deficiency Associated COPD. Clinics in Chest Medicine, 2020, 41, 339-345.	0.8	16
110	Detection of Alpha-1 Antitrypsin Deficiency by Respiratory Therapists: Experience With an Educational Program. Respiratory Care, 2014, 59, 667-672.	0.8	15
111	Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation. American Journal of Transplantation, 2021, 21, 1713-1724.	2.6	15
112	PRIMUS “ Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation. International Journal of COPD, 2022, Volume 17, 329-342.	0.9	15
113	Pleural Macrophages Differentially Alter Pleural Mesothelial Cell Glycosaminoglycan Production. Experimental Lung Research, 1996, 22, 101-111.	0.5	14
114	A 56-Year-Old Woman With Arm Pain, Dyspnea, and an Elevated Diaphragm. Chest, 2008, 133, 296-299.	0.4	14
115	COPD in individuals with the PiMZ alpha-1 antitrypsin genotype. European Respiratory Review, 2017, 26, 170068.	3.0	14
116	Double-lumen endotracheal tubes. Clinics in Chest Medicine, 1991, 12, 497-506.	0.8	14
117	Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transplantation, 2001, 7, 1081-1084.	1.3	13
118	Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?. Pulmonary Medicine, 2010, 2010, 1-6.	0.5	13
119	Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease. European Respiratory Review, 2017, 26, 170061.	3.0	13
120	Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice. Stem Cells Translational Medicine, 2021, 10, 320-331.	1.6	13
121	Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol. Annals of the American Thoracic Society, 2015, 12, 1551-1560.	1.5	12
122	Impact of obstructive sleep apnea syndrome on cognition in early postmenopausal women. Sleep and Breathing, 2016, 20, 621-626.	0.9	12
123	<p>Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 959-964.	0.9	12
124	Prevalence of self-reported sleep problems amongst adults with obstructive airway disease in the NHANES cohort in the United States. Sleep and Breathing, 2020, 24, 985-993.	0.9	12
125	Endobronchial coils for emphysema: Dual mechanism of action on lobar residual volume reduction. Respirology, 2020, 25, 1160-1166.	1.3	12
126	Scleroderma Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1178-1179.	2.5	11



#	ARTICLE	IF	CITATIONS
127	Effect of Obstructive Sleep Apnea Treatment on Mail-In Cognitive Function Screening Instrument. American Journal of the Medical Sciences, 2014, 348, 215-218.	0.4	11
128	Islet Harvest in Carbon Monoxide-Saturated Medium for Chronic Pancreatitis Patients Undergoing Islet Autotransplantation. Cell Transplantation, 2019, 28, 25S-36S.	1.2	11
129	The United States Alpha-1 Foundation Research Registry: Genesis, Impact and Future. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 42-45.	0.7	10
130	Proteomic biomarkers of cognitive impairment in obstructive sleep apnea syndrome. Sleep and Breathing, 2019, 23, 251-257.	0.9	10
131	A population-based estimate of the health care burden of obstructive sleep apnea using a STOP-BAG questionnaire in South Carolina. Journal of Clinical Sleep Medicine, 2021, 17, 367-374.	1.4	10
132	Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States. Southern Medical Journal, 2018, 111, 293-298.	0.3	10
133	Electron Microscopic Analysis of the Normal and the Activated Pleural Macrophage. Experimental Lung Research, 1993, 19, 731-742.	0.5	9
134	Executive Summary. Chest, 2012, 142, 1284-1288.	0.4	9
135	Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. International Journal of COPD, 2015, 10, 2055.	0.9	9
136	Chylous Transport of Amiodarone. Chest, 1992, 101, 573-574.	0.4	8
137	Platelets attenuate oxidant-induced permeability in endothelial monolayers: glutathione-dependent mechanisms. Journal of Applied Physiology, 1996, 81, 1701-1706.	1.2	8
138	Alpha-1 Foundation Research Registry: From the Past to the Future. Journal of Pediatric Gastroenterology and Nutrition, 2002, 34, 1.	0.9	8
139	?The Lion, the Witch and the Wardrobe?: Impact on sibs of individuals with AAT deficiency. American Journal of Medical Genetics Part A, 2004, 130A, 251-257.	2.4	7
140	Treatment for Secondary Pulmonary Hypertension. Chest, 2005, 128, 1897-1898.	0.4	7
141	Opportunities and Challenges in the Study of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 91-92.	2.5	7
142	The Alpha-1 Association Genetic Counseling Program: An Innovative Approach to Service. Journal of Genetic Counseling, 2011, 20, 330-336.	0.9	7
143	Treatment of Alpha-1 Antitrypsin Deficiency. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 470-477.	0.8	7
144	Rapid oral desensitization to sirolimus in a patient with lymphangiomyomatosis. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 352-353.	2.0	7

#	ARTICLE	IF	CITATIONS
145	Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations. <i>Pulmonary Medicine</i> , 2018, 2018, 1-6.	0.5	7
146	Community-acquired Pneumonia Guideline Recommendationsâ€™ Impact of a Consensus-based Process versus Systematic Reviews. <i>Clinical Infectious Diseases</i> , 2021, 73, e1467-e1475.	2.9	7
147	<p>Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 3193-3199.	0.9	7
148	Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 2, 177-190.	0.5	7
149	Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 680-9.	0.7	7
150	Barriers to Genetic Testing Among Persons at Risk for Alpha-1 Antitrypsin Deficiency. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 501-505.	1.7	6
151	Impact of medications on cognitive function in obstructive sleep apnea syndrome. <i>Sleep and Breathing</i> , 2015, 19, 939-945.	0.9	6
152	Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 293-304.	0.5	6
153	<p>Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1377-1388.	0.9	6
154	Serum Proteins Associated with Emphysema Progression in Severe Alpha-1 Antitrypsin Deficiency. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2017, 4, 204-216.	0.5	6
155	Management of parapneumonic pleural effusions and empyema. <i>Infectious Disease Clinics of North America</i> , 1991, 5, 539-59.	1.9	6
156	Rest in Peace. <i>Journal of Bronchology</i> , 2005, 12, 131-132.	0.2	5
157	A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1833-1843.	0.9	5
158	&lt;p&gt;Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2389-2397.	0.9	5
159	&lt;p&gt;Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 3313-3322.	0.9	5
160	Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. <i>Thorax</i> , 2021, 76, 134-143.	2.7	5
161	Alcohol Use Predicts ER Visits in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) Associated COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 417-425.	0.7	4
162	Cystâ€¢based measurements for assessing lymphangioleiomyomatosis in computed tomography. <i>Medical Physics</i> , 2015, 42, 2287-2295.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD. International Journal of COPD, 2021, Volume 16, 3263-3273.	0.9	4
164	Proteomic Analysis of Exosomes Secreted from Human Alpha-1 Antitrypsin Overexpressing Mesenchymal Stromal Cells. Biology, 2022, 11, 9.	1.3	4
165	Radiation therapy for palliation of Eisenmenger's syndrome-associated painful splenomegaly. Radiation Medicine, 2008, 26, 84-87.	0.8	3
166	COPD and Lung Cancer. Chest, 2010, 138, 1289-1290.	0.4	3
167	Unilateral Pulmonary Artery Aplasia in a Pregnant Patient. Case Reports in Medicine, 2011, 2011, 1-3.	0.3	3
168	Genetics' Influence on Patient Experiences with a Rare Chronic Disorder. Nursing Clinics of North America, 2013, 48, 627-636.	0.7	3
169	Multiorgan System Dysfunction in the Chylomicronemia Syndrome. Journal of Intensive Care Medicine, 2014, 29, 175-178.	1.3	3
170	<p></p>Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort</p>. International Journal of COPD, 2019, Volume 14, 2625-2637.	0.9	3
171	A doen'ça pulmonar intersticial na esclerose sist'mica ' lentamente progressiva?. Jornal Brasileiro De Pneumologia, 2011, 37, 142-143.	0.4	3
172	A Novel Cellular Therapy to Treat Pancreatic Pain in Experimental Chronic Pancreatitis Using Human Alpha-1 Antitrypsin Overexpressing Mesenchymal Stromal Cells. Biomedicines, 2021, 9, 1695.	1.4	3
173	Infection in the Intensive Care Unit: A Clinician's View of the Role of Imaging. Seminars in Roentgenology, 2007, 42, 7-10.	0.2	2
174	Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 427-434.	0.9	2
175	Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. International Journal of COPD, 2016, Volume 12, 135-140.	0.9	2
176	Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy, 2019, 20, 1075-1085.	0.9	2
177	Rare Disease Registries: Steps Forward. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 126-128.	0.5	2
178	A Retrospective Claims Analysis of Dual Bronchodilator Fixed-Dose Combination Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 221-232.	0.5	2
179	The Rise and Fall of Ultrasound Thoracentesis. Journal of Bronchology, 2005, 12, 191-192.	0.2	1
180	Prognostic Significance of Bronchoalveolar Lavage Cellular Analysis in Scleroderma Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1293-1293.	2.5	1

#	ARTICLE	IF	CITATIONS
181	Massive Hemoptysis. , 2008, , 929-948.		1
182	Rude Awakening: Acute Abdominal Pain with Spontaneous Resolution. American Journal of Medicine, 2012, 125, 971-973.	0.6	1
183	The prospective association of perceived criticism with dyspnea in chronic lung disease. Journal of Psychosomatic Research, 2013, 74, 450-453.	1.2	1
184	Reply: Asthma/COPD Overlap Syndrome and Medicare 30-Day Readmissions. Annals of the American Thoracic Society, 2016, 13, 1192-1192.	1.5	1
185	Evidence-Based Medicine and the American Thoracic Society Guidelines. JAMA Internal Medicine, 2019, 179, 1003.	2.6	1
186	Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease. Healthcare (Switzerland), 2019, 7, 12.	1.0	1
187	Relationship between alpha-1 antitrypsin deficiency and obstructive sleep apnea. Sleep and Breathing, 2021, 25, 2091-2097.	0.9	1
188	Alpha-1 Antitrypsin Deficiency. , 2010, , 209-224.		1
189	Hypertension Prevalence in the US Population Varies with Differences in Alpha-1 Antitrypsin Genotype: A Cross Sectional Study. British Journal of Medicine and Medical Research, 2015, 5, 880-888.	0.2	1
190	Connective Tissue Disease and Vasculitis-Associated Interstitial Lung Disease. , 2009, , 159-175.		1
191	Updates in the Management of Alpha-1 Antitrypsin Deficiency Lung Disease. US Respiratory & Pulmonary Diseases, 2021, 6, 26.	0.2	1
192	Refractory Hypotension During Warfarin Therapy. Hospital Practice (1995), 1994, 29, 121-121.	0.5	0
193	Hypoglycemia risk: A cause for concern in the intensive care unit hyperglycemia control debate. Critical Care Medicine, 2007, 35, 1222-e11.	0.4	0
194	S64â€...Circulating polymers are found in alpha-1-antitrypsin deficiency and are associated with lung disease. Thorax, 2013, 68, A35.1-A35.	2.7	0
195	How should we treat vascular and fibrotic lung disease in scleroderma?. F1000 Medicine Reports, 2009, 1, .	2.9	0
196	Establishing the USA Registry: Logistics, Impact, and Early Clinical Trials. , 2017, , 207-211.		0
197	A Novel Detection Method to Identify Individuals with Alpha-1 Antitrypsin Deficiency: Linking Prescription of COPD Medications with the Patient-Facing Electronic Medical Record. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, , .	0.5	0
198	A Semi-Quantitative Immunohistochemistry-Based Comparison of Systemic Sclerosis-Associated (SSc-PAH) vs. Idiopathic Pulmonary Arterial Hypertension (IPAH) Lungs. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
199	COVID-19 Impact on Health of Alpha-1 Antitrypsin Deficient Patients in a Disease Management Program. , 2022, , .		0